Adamis Pharmaceuticals Corporation (ADMP)
(Delayed Data from NSDQ)
$2.07 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.08 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.07 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.08 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Adamis Gets FDA Nod for Generic Version of Mylan's EpiPen
by Zacks Equity Research
Shares of Adamis Pharmaceuticals Corporation (ADMP) soared more than 50% after the FDA approved the company's Epinephrine injection, USP, (0.3 mg Pre-filled single dose syringe) which is the generic version of Mylan N.V.'s (MYL) EpiPen.
Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session
by Zacks Equity Research
Adamis Pharmaceuticals Corporation (ADMP) moved big last session, as its shares rose over 6% on the day
Adamis Pharmaceuticals (ADMP) Shares March Higher, Can It Continue?
by Zacks Equity Research
Adamis Pharmaceuticals Corporation (ADMP) has been on the move lately as the stock has risen by 21% in the past four weeks, and it is currently trading well above its 20-Day SMA
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?
by Zacks Equity Research
Investors in Adamis Pharmaceuticals Corporation (ADMP) need to pay close attention to the stock based on moves in the options market lately.